1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Glofitamab (Glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: Preliminary safety and efficacy results
    Meeting Abstract

    Falchi, L.; Jardin, F.; Haioun, C.; Wrobel, T.; Mészáros Joergensen, J.; Bastos-Oreiro, M.; Mou, E.; Martinez-Lopez, J.; Budde, L. E.; Bartlett, N. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis
    Meeting Abstract

    Hobbs, G. S.; Kim, H. T.; O'Connor, S.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; El-Jawahri, A.; McAfee, S.; Hem, J.; Lozano, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A personalized whole genome-informed assay targeting single mutant in circulating tumor DNA can identify MRD and predict relapse in DLBCL
    Meeting Abstract

    Merryman, R. W.; Rhoades, J.; Xiong, K.; Antel, K.; An, H. H.; Redd, R. A.; McDonough, M. M.; Guerrero, L.; Crnjac, A.; Sridhar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) who had received 2-4 prior regimens: Updated results from the phase 3 KarMMa-3 trial
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Early results indicate acceptable safety and promising efficacy of venetoclax in combination with pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma
    Meeting Abstract

    Zelenetz, A. D.; Diefenbach, C. S.; Herbaux, C.; Tani, M.; Houot, R.; Bastos-Oreiro, M.; Tilly, H.; Gastinne, T.; Thieblemont, C.; Troy-Barnes, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • I-DATA Study: Randomized, sequential, open-label study to evaluate the efficacy of IDH targeted/non- targeted versus non-targeted/IDH-targeted approaches in the treatment of newly diagnosed IDH mutated adult AML patients not candidates for intensive induction therapy
    Meeting Abstract

    Ozga, M. P.; Dvorak-Kornaus, K. M.; Zhao, Q.; Buss, J.; Laganson, A.; Hamp, E.; Madanat, Y. F.; Pollyea, D. A.; Stein, E. M.; Zeidner, J. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from istopmm, a population-based screening study in Iceland
    Meeting Abstract

    Rögnvaldsson, S.; Gasparini, A.; Thorsteinsdottir, S.; Sverrisdottir, I.; Eythorsson, E.; Long, T. E.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardottir, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with triple-class-exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who received at least 3 lines of prior antimyeloma regimens in the KarMMa-3 phase 3 randomized controlled trial
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 trial of 28-day (Arm A) versus 14-Day (Arm B) schedule of venetoclax plus azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years
    Meeting Abstract

    Borate, U. M.; Huang, Y.; Johnson, M. F.; Zeidner, J. F.; Swords, R. T.; Koenig, K. L.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Plasma circulating tumor DNA (ctDNA) as an alternative to tissue DNA for genotyping of DLBCL: Results from the POLARIX study
    Meeting Abstract

    Jardin, F.; Raghavan, V.; Tracy, S.; Balasubramanian, S.; Sehn, L. H.; Flowers, C. R.; Morschhauser, F.; Herrera, A. F.; Trněný, M.; Sharman, J. P.; more...
    Blood (2023)

    Fulltext@MSK | Save